Amgen has been in the spotlight due to various reasons. The biotechnology firm has gained substantial investment from numerous financial firms, despite a few opting to reduce their holdings. Most notable is its work on the drug,
Rocatinlimab, which is used to treat atopic dermatitis. Data obtained from
Rocatinlimab ASCEND phase 3 study has been largely positive, making it a compelling prospect for investments. The stock recently received 'Buy' and 'Overweight' ratings from William Blair and Piper Sandler, respectively.
Apart from Rocatinimab, Amgen’s research and development (R&D) have extended to the potential obesity drug,
MariTide, which has shown weight loss potential. Additionally, FDA’s expansion of
Repatha use has added value to the firm. Conversely, the company’s stock performance appeared inconsistent, occasionally sliding as the market rises.
Notably, the company also unveiled a
$600 million innovation hub aimed at expanding R&D efforts in California, which seems it is committed to exploring new opportunities and broadening its horizon.
Overall, these recent developments indicate a potentially profitable future for this blue-chip biotech innovation firm.
Amgen AMGN News Analytics from Mon, 23 Jun 2025 07:00:00 GMT to Sat, 13 Sep 2025 23:15:59 GMT -
Rating 6
- Innovation 7
- Information 5
- Rumor 3
